Repligen Soars 5% as RBC Raises Price Target to $200 After Full-Year Guidance Hike

Repligen (RGEN) shares rose 5% after RBC Capital raised its price target to $200, citing strong Q3 results and raised full-year guidance. The company reported 11% revenue growth and expects 12%-13% organic growth in 2026. Competitors like Avantor, Thermo Fisher, and Danaher are growing more slowly.

Original reporting
Published Oct 29, 2026, 6:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Repligen Soars 5% as RBC Raises Price Target to $200 After Full-Year Guidance Hike — source image
Decision brief

The 30-second read

$RGENBullishMed
01

Why it matters

The earnings beat and guidance raise suggest a stronger growth trajectory, prompting analysts to lift price targets and investors to bid up the stock.

02

Market read

Repligen's earnings beat and guidance lift are fresh, material news likely to drive short‑term upside and influence peer valuations.

03

What to watch

Repligen's recent BioLife acquisition adds integration risk that could temper upside.

Relevance 7/10Novelty 7/10Timing: after-hours today

Background

Repligen reported a record Q3 with 11% revenue growth, beat expectations, and announced a higher 2026 revenue range of $844‑$852 million.

Company-level read

Ticker impact

$RGENBullishHigh confidence
Context

RBC raised its price target to $200 after Repligen beat estimates and lifted full-year revenue guidance, driving a 5% share jump.

Expected impact

upward pressure as investors price in stronger growth and higher target

Evidence & confidence

Guidance lift and analyst target increase are fresh, material news for a mid‑cap biotech, and the stock already rallied 5% on the announcement.

Market effects

Bioprocessing peers may face relative underperformance as Repligen outpaces them.

U.S. biotech sector gains modest boost from the surprise guidance lift.

Limited to investors focused on specialty biotech and growth stocks.

Counterpoint

The guidance hike may be optimistic given competitive pressure; a pullback could follow if growth slows.

Key entities

  • RBC Capital Markets

    Raised price target to $200 and maintained Outperform rating.

  • BioLife

    Acquisition closed in October, contributing to 2027 revenue outlook.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.